Spinal cord injury results in devastating neurological deficits accompanied by lifelong disability and significant economic burden. While the development of novel compounds or cell-based interventions for spinal cord injury is unquestionably worthwhile, a complementary approach examines current standards of care and the degree to which these can be optimized to benefit long-term neurological function. Numerous classes of drugs, already in use in the acute phase of spinal cord injury, are intriguing because they (1) readily cross the blood-spinal cord barrier to modulate activity in the central nervous system and (2) are administered during a window of time in which neuroprotection, and even some repair, are feasible. Here, we review a rare case of convergent lines of evidence from both preclinical and human studies to support the early administration of a class of drug (ie, gabapentinoids) to both foster motor recovery and reduce the severity of neuropathic pain.

中文翻译：

---

加巴喷丁在脊髓损伤中的有益“药物多效性”：完善护理标准的案例

脊髓损伤导致毁灭性的神经功能缺损，伴随终身残疾和重大经济负担。虽然开发用于脊髓损伤的新型化合物或基于细胞的干预措施无疑是值得的，但补充方法检查了当前的护理标准以及这些标准可以优化以有益于长期神经功能的程度。已经在脊髓损伤急性期使用的多种药物令人感兴趣，因为它们 (1) 容易穿过血-脊髓屏障以调节中枢神经系统的活动，以及 (2) 在神经保护，甚至一些修复是可行的时间。在这里，